High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 365-371

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Garcia Gonzalez, Martín J ^a   Kaski, Juan Carlos ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Acute coronary syndrome prognosis; Diabetes mellitus; Inflammation; Matrix metalloproteinases; ST segment elevation myocardial infarction

Indexed keywords

GELATINASE B;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

AGED; ANGINA PECTORIS, VARIANT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SHOCK, CARDIOGENIC;

EID: 38049042798     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.012     Document Type: Article

References (33)

1. Diez J. Emerging role of metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Invest 32 (2002) 291-294
2. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Randomski M.W., and Shulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101 (2000) 1833-1839
3. Lindsey M., Wedin K., Brown M.D., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103 (2001) 2181-2187
4. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
5. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., and Kamada T. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
6. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
7. Garcia M.J., McNamara P.M., Gordon T., and Kannel W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23 (1974) 105-111
8. Franklin K., Goldberg R.J., Spencer F., et al. Implications of diabetes in patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med 164 (2004) 1457-1463
9. Marx N., Froehlich J., Siam L., et al. Antidiabetic PPAP gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 283-288
10. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardilogy Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-69.
11. Killip T., and Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 20 (1967) 457-464
12. Wahr D.W., Wang Y.S., and Schiller N.B. Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population. J Am Coll Cardiol 1 (1983) 863-868
13. Hasdai D., Topol E.J., Califf R.M., Berger P.B., and Holmes Jr. D.R. Cardiogenic shock complicating acute coronary syndromes. Lancet 356 (2000) 749-756
14. Fujimoto N., Hosokawa N., Iwata K., Shinya T., Okada Y., and Hayakama T. A one-step sandwich enzyme immunoassay for the inactive precursor and complexes forms of human matrix metalloprotease 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 231 (1994) 79-88
15. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
16. American Diabetes Association. Screening for type 2 diabetes: Diabetes Care 2004;(Suppl. 1):S11-S14.
17. Hasdai D., Califf R.M., Thompson T.D., et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 35 (2000) 136-143
18. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
19. Abbott R.D., Donahue R.P., Kannel W.B., and Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 260 (1988) 3456-3460
20. Yarom R., Zirkin H., Stammler G., and Rose A.G. Human coronary microvessels in diabetes and in ischaemia. Morphometric study of autopsy material. J Pathol 166 (1992) 265-270
21. Landmesser U., Hornig B., and Drexler H. Endothelial function: a critical determinant in atherosclerosis?. Circulation 109 Suppl. 1 (2004) II27-II33
22. Stone P.H., Muller J.E., Hartwell T., et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14 (1989) 49-57
23. Moreno P.R., Murcia A.M., and Palacios I.F. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
24. Attali J.R., Sachs R.N., Valensi P., et al. Asymptomatic diabetic cardiomyopathy: a noninvasive study. Diabetes Res Clin Pract 4 (1988) 421-424
25. Bouchard A., Sanz N., Botvinick E.H., et al. Noninvasive assessment of cardiomyopathy in normotensive diabetic patients between 20 and 50 years old. Am J Med 87 (1989) 160-166
26. Feldman A.M., Li Y.Y., and McTiernan C.F. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 357 (2001) 654-655
27. Siwik D.A., Pagano P.J., and Colucci W.S. Oxidative stress regulates collagen síntesis and matriz metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280 (2001) 53-60
28. Wilson E.M., Gunasinghe H.R., Coker M.L., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8 (2001) 390-398
29. Lendon C.L., Davies M.J., Born G.V., and Richardson P.D. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 87 (1991) 87-90
30. Death A.K., Fisher E.J., McGrath K.C., and Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168 (2003) 263-269
31. Portik-Dobos V., Anstadt M., Hutchinson J., Bannan M., and Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51 (2002) 3063-3068
32. Tayebjee M.H., Lim H.S., MacFayden R.J., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy. Diabetes Care 27 (2004) 2049-2051
33. Creemers E.E., Cleutjens J.P., Smits J.F., and Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210